Wednesday, March 23, 2011

Xoma, Servier diabetes drug fails trial - - PMLiVE

A potential therapy for diabetes being developed by the biotech company Xoma in partnership with the French pharma firm Servier failed to meet the primary endpoint in a phase IIb study.

The therapy, a monoclonal antibody known as Xoma 052, did not sufficiently reduce glycosylated haemoglobin, or HbA1c, in type II diabetes patients in the placebo-controlled study.

Posted via email from Jack's posterous

No comments: